n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
NEWPORT BEACH, Calif. , March 11, 2024–(BUSINESS WIRE)–Evolus, Inc. (Nasdaq: EOLS) announced the value of its subscribed offering of 3,554,000 shares of common stock at a subscribed offering value of $14. 07 per share, which is equivalent to the final value on Friday, March 8, 2024, before discounts and subscription fees. Gross proceeds from the offering to Evolus are expected to be approximately $50. 0 million, before deducting discounts, subscription commissions and offering fees. In addition, Evolus has granted subscribers a 30-day option to purchase up to 533,100 common inventories in addition to the subscribed offer value, minus discounts and subscription fees. The offering is expected to close on or about March 13, 2024, subject to satisfaction of standard ending conditions. All inventories in the supply are sold through Evolus.
Evolus intends to use the proceeds from the offering to continue to fund Jeuveau’s® growth, Evolysse’s™ launch activities, potential business progression opportunities, and overall corporate purposes.
Leerink Partners and Stifel are the joint lead managers of the offering.
The disposition was made pursuant to the prospectus accompanying Evolus’ registration on Form S-3 (Docket No. 333-270370), which was filed on March 8, 2023, was amended on April 14, 2023, and June 7, 2023, and became effective. June 8, 2023. Es copies of the accompanying prospectus may be received by visiting EDGAR on the U. S. Securities and Exchange Commission’s website. A supplement to the prospectus (“SEC”) in www. sec. gov. Se will file a supplement to the prospectus with the SEC and become part of the form of effective registrationArray, copies of the prospectus supplement may be received from Leerink Partners LLC, Attn: Syndicate Decomponentment, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525 ext. 200. 6105, or by e-mail to syndicate@leerink. com; o Stifel, Nicolaus
This press release shall constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale was previously unlawful. to the registration or qualification of such securities under the securities laws of such state or jurisdiction.
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a good-looking corporate global functionality that evolves the aesthetic neurotoxins market for the next generation of good-looking consumers through its unique customer-centric business style and state-of-the-art virtual platformArray. Our project is to become a global multi-product. Aesthetics corporation founded on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a facility employing Hi-Pure™ technology. Evolus expands its product portfolio after signing a definitive agreement to become Evolysse’s™ exclusive distributor in the U. S. The U. S. Marine Corps is the exclusive European distributor of Estyme®, a line of exclusive dermal fillers that has lately been in an advanced stage of progressionArray
Forward-Looking Statements
Statements in this press release that relate to long-term plans, events, customers or functionality are forward-looking statements as explained in the Private Securities Litigation Reform Act of 1995. All statements, other than statements of fact old, are statements that can simply be considered forward-looking. -forward-looking statements, adding statements related to the public offering of Evolus and statements involving the words “plans”, “expects”, “believes”, “strategy”, “opportunity”, “anticipates” Array “outlook”, “designed” , or other bureaucracy of those words or similar expressions, although not all forward-looking statements involve those identifying words. These forward-looking statements are subject to the uncertainties inherent in the prediction of long-term effects and situations and there can be no assurance that the public offering mentioned above will be carried out in the terms described. The final touch of the public offer and its conditions is subject to problems, many of which are beyond the control of Evolus, including, among others, market situations, non-compliance with the standard final conditions and risk and other issues set forth in the definitive prospectus supplement and accompanying prospectus are included in the registration statement. Except as required by law, Evolus undertakes no legal responsibility to update or revise any forward-looking statements to reflect new information, a replacement in cases or unforeseen events.
Jeuveau® and Nuceiva® are registered by Evolus, Inc. Evolysse™ is a trademark of Evolus, Inc. Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co. , Ltd.
View businesswire. com edition: https://www. businesswire. com/news/home/20240311488324/en/
Contactos
Investor Contact: Nareg SagherianVice President, Head of Global Investor Relations & Corporate CommunicationsTel: 248-202-9267Email: ir@evolus. com
Media Contact: Email: media@evolus. com